$VRDN
Viridian Therapeutics, Inc.\DE

2019 Q1 Form 10-K Financial Statement

#000159075019000013 Filed on March 14, 2019

View on sec.gov

Income Statement

Concept 2019 Q1 2017 Q4 2017 Q3
Revenue $372.0K $1.192M $1.631M
YoY Change -92.22% 134.18% 74.25%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.360M $2.550M $2.500M
YoY Change 12.37% 1.19% 3.05%
% of Gross Profit
Research & Development $8.751M $4.998M $5.018M
YoY Change 36.46% 27.96% 69.24%
% of Gross Profit
Depreciation & Amortization $73.00K $80.00K $100.0K
YoY Change 5.8% -60.0% 0.0%
% of Gross Profit
Operating Expenses $12.11M $4.998M $7.520M
YoY Change 28.77% 27.96% 49.86%
Operating Profit -$11.74M -$5.889M
YoY Change 154.08% 44.27%
Interest Expense $110.0K -$30.00K $60.00K
YoY Change -375.0% -50.0% 160.87%
% of Operating Profit
Other Income/Expense, Net $339.0K -$32.00K $113.0K
YoY Change 102.99% -46.67% 1514.29%
Pretax Income -$11.63M -$6.390M -$5.830M
YoY Change 149.57% 7.04% 40.48%
Income Tax
% Of Pretax Income
Net Earnings -$11.63M -$6.386M -$5.834M
YoY Change 149.5% 6.9% 40.48%
Net Earnings / Revenue -3126.08% -535.74% -357.69%
Basic Earnings Per Share
Diluted Earnings Per Share -$5.646M -$4.289M -$4.049M
COMMON SHARES
Basic Shares Outstanding 30.92M shares 22.31M shares 21.48M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q1 2017 Q4 2017 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $51.00M $47.40M $42.80M
YoY Change -34.7% 114.48% 692.59%
Cash & Equivalents $18.20M $47.44M $42.81M
Short-Term Investments $32.80M
Other Short-Term Assets $3.200M $3.000M $3.000M
YoY Change -5.88% 66.67% 650.0%
Inventory
Prepaid Expenses
Receivables $6.000K $1.456M $635.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $54.21M $51.87M $46.42M
YoY Change -37.22% 117.23% 612.85%
LONG-TERM ASSETS
Property, Plant & Equipment $691.0K $563.0K $610.0K
YoY Change 17.32% -9.92% -39.84%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $50.00K $50.00K $50.00K
YoY Change 0.0% -80.62%
Total Long-Term Assets $741.0K $613.0K $660.0K
YoY Change 15.96% -30.58% -35.86%
TOTAL ASSETS
Total Short-Term Assets $54.21M $51.87M $46.42M
Total Long-Term Assets $741.0K $613.0K $660.0K
Total Assets $54.95M $52.48M $47.08M
YoY Change -36.83% 111.96% 524.33%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $517.0K $906.0K $409.0K
YoY Change -31.97% -10.03% 701.96%
Accrued Expenses $3.044M $2.991M $4.142M
YoY Change -9.86% -23.48% 151.18%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due $3.300M $0.00 $2.000M
YoY Change -100.0%
Total Short-Term Liabilities $6.860M $3.897M $6.534M
YoY Change 65.82% -43.4% 129.02%
LONG-TERM LIABILITIES
Long-Term Debt $7.100M $9.900M $1.400M
YoY Change -29.0% 253.57%
Other Long-Term Liabilities $41.00K $152.0K $171.0K
YoY Change -68.7% 8450.0%
Total Long-Term Liabilities $41.00K $152.0K $171.0K
YoY Change -68.7% 8450.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.860M $3.897M $6.534M
Total Long-Term Liabilities $41.00K $152.0K $171.0K
Total Liabilities $13.99M $13.97M $8.096M
YoY Change -2.04% 43.96% 183.57%
SHAREHOLDERS EQUITY
Retained Earnings -$137.9M -$93.59M -$87.21M
YoY Change 40.38% 39.53% 247.83%
Common Stock $309.0K $226.0K $219.0K
YoY Change 2.32% 2725.0% 102.78%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $40.96M $38.51M $38.99M
YoY Change
Total Liabilities & Shareholders Equity $54.95M $52.48M $47.08M
YoY Change -36.83% 111.96% 524.33%

Cashflow Statement

Concept 2019 Q1 2017 Q4 2017 Q3
OPERATING ACTIVITIES
Net Income -$11.63M -$6.386M -$5.834M
YoY Change 149.5% 6.9% 40.48%
Depreciation, Depletion And Amortization $73.00K $80.00K $100.0K
YoY Change 5.8% -60.0% 0.0%
Cash From Operating Activities -$11.81M -$7.250M -$5.660M
YoY Change 60.43% -22.95% 405.36%
INVESTING ACTIVITIES
Capital Expenditures $37.00K -$40.00K -$60.00K
YoY Change -61.05% -84.0%
Acquisitions
YoY Change
Other Investing Activities -$2.780M $0.00 $0.00
YoY Change
Cash From Investing Activities -$2.820M -$40.00K -$60.00K
YoY Change 2868.42% -84.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $138.0K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $218.0K 11.91M 2.200M
YoY Change -99.43% -25.52% -11100.0%
NET CHANGE
Cash From Operating Activities -$11.81M -7.250M -5.660M
Cash From Investing Activities -$2.820M -40.00K -60.00K
Cash From Financing Activities $218.0K 11.91M 2.200M
Net Change In Cash -$14.41M 4.620M -3.520M
YoY Change -147.01% -27.01% 208.77%
FREE CASH FLOW
Cash From Operating Activities -$11.81M -$7.250M -$5.660M
Capital Expenditures $37.00K -$40.00K -$60.00K
Free Cash Flow -$11.85M -$7.210M -$5.600M
YoY Change 58.88% -21.29% 400.0%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018 dei Amendment Flag
AmendmentFlag
false
CY2018 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2018 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2018 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
CY2018 dei Document Period End Date
DocumentPeriodEndDate
2018-12-31
CY2018 dei Document Type
DocumentType
10-K
CY2018 dei Entity Central Index Key
EntityCentralIndexKey
0001590750
CY2019Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
30921219 shares
CY2018 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2018 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2018 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2018 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2018Q2 dei Entity Public Float
EntityPublicFloat
165500000 USD
CY2018 dei Entity Registrant Name
EntityRegistrantName
MIRAGEN THERAPEUTICS, INC.
CY2018 dei Entity Shell Company
EntityShellCompany
false
CY2018 dei Entity Small Business
EntitySmallBusiness
true
CY2018 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2018 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2017 mgen Accretionof Offering Costs
AccretionofOfferingCosts
5000 USD
CY2018 mgen Accretionof Offering Costs
AccretionofOfferingCosts
0 USD
CY2017Q4 mgen Accrued Legal Fees Current
AccruedLegalFeesCurrent
185000 USD
CY2018Q4 mgen Accrued Legal Fees Current
AccruedLegalFeesCurrent
376000 USD
CY2017Q4 mgen Accrued Liabilities Equipmentand Lab Materials
AccruedLiabilitiesEquipmentandLabMaterials
197000 USD
CY2018Q4 mgen Accrued Liabilities Equipmentand Lab Materials
AccruedLiabilitiesEquipmentandLabMaterials
33000 USD
CY2017Q4 mgen Accrued Liabilityof Warrantson Temporary Equity
AccruedLiabilityofWarrantsonTemporaryEquity
82000 USD
CY2018Q4 mgen Accrued Liabilityof Warrantson Temporary Equity
AccruedLiabilityofWarrantsonTemporaryEquity
82000 USD
CY2017Q4 mgen Accrued Outsourcing Clinicaland Preclinical Studies
AccruedOutsourcingClinicalandPreclinicalStudies
581000 USD
CY2018Q4 mgen Accrued Outsourcing Clinicaland Preclinical Studies
AccruedOutsourcingClinicalandPreclinicalStudies
1129000 USD
CY2017 mgen Adjustmentsto Additional Paidin Capital Reclassificationof Warrant Liability
AdjustmentstoAdditionalPaidinCapitalReclassificationofWarrantLiability
51000 USD
CY2017 mgen Amortization Of Stock Issuance Costs
AmortizationOfStockIssuanceCosts
0 USD
CY2018 mgen Amortization Of Stock Issuance Costs
AmortizationOfStockIssuanceCosts
55000 USD
CY2018Q4 mgen Capital Stock Shares Authorized
CapitalStockSharesAuthorized
105000000 shares
CY2017Q4 mgen Contract With Customer Asset Incurred But Not Yet Billed
ContractWithCustomerAssetIncurredButNotYetBilled
1100000 USD
CY2018Q4 mgen Contract With Customer Asset Incurred But Not Yet Billed
ContractWithCustomerAssetIncurredButNotYetBilled
500000 USD
CY2017 mgen Conversionof Warrantsto Permanent Equity
ConversionofWarrantstoPermanentEquity
51000 USD
CY2018 mgen Conversionof Warrantsto Permanent Equity
ConversionofWarrantstoPermanentEquity
0 USD
CY2017 mgen Deferred Tax Asset Valuation Allowance Percent
DeferredTaxAssetValuationAllowancePercent
1
CY2018 mgen Deferred Tax Asset Valuation Allowance Percent
DeferredTaxAssetValuationAllowancePercent
1.00
CY2017Q4 mgen Deferred Tax Assets Tax Deferred Expense Startup Costs
DeferredTaxAssetsTaxDeferredExpenseStartupCosts
829000 USD
CY2018Q4 mgen Deferred Tax Assets Tax Deferred Expense Startup Costs
DeferredTaxAssetsTaxDeferredExpenseStartupCosts
698000 USD
CY2017 mgen Effective Income Tax Rate Reconciliation Reduction In Net Operating Loss Percent
EffectiveIncomeTaxRateReconciliationReductionInNetOperatingLossPercent
0.067
CY2018 mgen Effective Income Tax Rate Reconciliation Reduction In Net Operating Loss Percent
EffectiveIncomeTaxRateReconciliationReductionInNetOperatingLossPercent
0.000
CY2018 mgen Lessee Operating Lease Number Of Renewal Terms
LesseeOperatingLeaseNumberOfRenewalTerms
2 renewal_term
CY2018 mgen License Fee Expense Milestone Reached
LicenseFeeExpenseMilestoneReached
700000 USD
CY2017Q4 mgen Long Term Debt Accumulated Accretion Of Final Payment Fee
LongTermDebtAccumulatedAccretionOfFinalPaymentFee
41000 USD
CY2018Q4 mgen Long Term Debt Accumulated Accretion Of Final Payment Fee
LongTermDebtAccumulatedAccretionOfFinalPaymentFee
367000 USD
CY2017 mgen Operating Leases Operating Expense
OperatingLeasesOperatingExpense
300000 USD
CY2018 mgen Operating Leases Operating Expense
OperatingLeasesOperatingExpense
300000 USD
CY2018 mgen Sharebased Compensation Arrangement By Sharebased Payment Award Number Of Shares Authorized Percent Of Common Stock Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAuthorizedPercentOfCommonStockOutstanding
0.04
CY2018Q4 mgen Sharebased Compensation Arrangementby Sharebased Payment Award Equity Awards Outstanding
SharebasedCompensationArrangementbySharebasedPaymentAwardEquityAwardsOutstanding
1887617 shares
CY2018 mgen Tax Credit Carryforward Limitations On Use Amount
TaxCreditCarryforwardLimitationsOnUseAmount
4600000 USD
CY2018 mgen Tax Credit Carryforward Write Off
TaxCreditCarryforwardWriteOff
2800000 USD
CY2017 mgen Tax Cuts And Jobs Act Of2017 Change In Tax Rate Deferred Tax Asset Income Tax Expense
TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxAssetIncomeTaxExpense
10800000 USD
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
906000 USD
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
571000 USD
CY2017Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1456000 USD
CY2018Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
24000 USD
CY2017 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
0 USD
CY2018 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
416000 USD
CY2017 us-gaap Accretion Expense
AccretionExpense
94000 USD
CY2018 us-gaap Accretion Expense
AccretionExpense
376000 USD
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2991000 USD
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3868000 USD
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
232000 USD
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
246000 USD
CY2017Q4 us-gaap Accrued Rent Current
AccruedRentCurrent
74000 USD
CY2018Q4 us-gaap Accrued Rent Current
AccruedRentCurrent
124000 USD
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2835000 USD
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3090000 USD
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0 USD
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3000 USD
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
131877000 USD
CY2018Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
177335000 USD
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2409000 USD
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3679000 USD
CY2017 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
127000 USD
CY2018 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
0 USD
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2409000 USD
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3679000 USD
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
32606000 USD
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
25337000 USD
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
22568006 shares
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2912000 shares
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3576000 shares
CY2017Q4 us-gaap Assets
Assets
52481000 USD
CY2018Q4 us-gaap Assets
Assets
66147000 USD
CY2017Q4 us-gaap Assets Current
AssetsCurrent
51868000 USD
CY2018Q4 us-gaap Assets Current
AssetsCurrent
65370000 USD
CY2018Q4 us-gaap Available For Sale Equity Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleEquitySecuritiesAccumulatedGrossUnrealizedLossBeforeTax
3000 USD
CY2018Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
29900000 USD
CY2018Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
29900000 USD
CY2017 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
1280000 USD
CY2018 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
0 USD
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22104000 USD
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
47441000 USD
CY2018 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-14835000 USD
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2018Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
705317 shares
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
30839463 shares
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
22568006 shares
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
30839463 shares
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
226000 USD
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
308000 USD
CY2017 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-26512000 USD
CY2018 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-32706000 USD
CY2017Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
10000000 USD
CY2018Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
10000000 USD
CY2017Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
119000 USD
CY2018Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
69000 USD
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
22500000 USD
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
22509000 USD
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
33100000 USD
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
33136000 USD
CY2017Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 USD
CY2018Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 USD
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
18257000 USD
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
24137000 USD
CY2017Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
2287000 USD
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.27
CY2017Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.29
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.38
CY2018 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.350
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.145
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.325
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.407
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.007
CY2018Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
6571000 USD
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
439000 USD
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
876000 USD
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
697000 USD
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
854000 USD
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
22509000 USD
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
33136000 USD
CY2017 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
308000 USD
CY2017 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
300000 USD
CY2018 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
281000 USD
CY2018 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
300000 USD
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.60
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.34
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.18
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.29
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.29
CY2018Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.33
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.10
CY2017 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2017 us-gaap Effective Income Tax Rate Reconciliation Deductions Qualified Production Activities
EffectiveIncomeTaxRateReconciliationDeductionsQualifiedProductionActivities
0.029
CY2018 us-gaap Effective Income Tax Rate Reconciliation Deductions Qualified Production Activities
EffectiveIncomeTaxRateReconciliationDeductionsQualifiedProductionActivities
0.000
CY2017 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.019
CY2018 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.010
CY2017 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
0.006
CY2018 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
-0.001
CY2017 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.031
CY2018 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.030
CY2017 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.048
CY2018 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
-0.103
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1538000 USD
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1704000 USD
CY2018Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
8300000 USD
CY2018 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y7M1D
CY2017Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3281000 USD
CY2017Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2581000 USD
CY2017Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2502000 USD
CY2017 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1436000 USD
CY2018 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1432000 USD
CY2017 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2205000 USD
CY2017Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2548000 USD
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10912000 USD
CY2018Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2990000 USD
CY2018Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2668000 USD
CY2018Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2696000 USD
CY2018Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2695000 USD
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11049000 USD
CY2017 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 USD
CY2018 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 USD
CY2017 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0 USD
CY2018 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0 USD
CY2017 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-101000 USD
CY2018 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-335000 USD
CY2018 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
791000 USD
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
724000 USD
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-51000 USD
CY2017 us-gaap Interest And Debt Expense
InterestAndDebtExpense
383000 USD
CY2018 us-gaap Interest And Debt Expense
InterestAndDebtExpense
873000 USD
CY2017 us-gaap Interest Paid Net
InterestPaidNet
446000 USD
CY2018 us-gaap Interest Paid Net
InterestPaidNet
489000 USD
CY2017 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
300000 USD
CY2018 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
300000 USD
CY2018Q4 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P3Y
CY2017Q4 us-gaap Liabilities
Liabilities
13971000 USD
CY2018Q4 us-gaap Liabilities
Liabilities
14803000 USD
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
52481000 USD
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
66147000 USD
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3897000 USD
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6733000 USD
CY2018Q4 us-gaap Long Term Debt
LongTermDebt
10000000 USD
CY2018Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
2333000 USD
CY2018Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
3667000 USD
CY2018Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
4000000 USD
CY2017Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
9922000 USD
CY2018Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
8004000 USD
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
52470000 USD
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
41916000 USD
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
1034000 USD
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-29907000 USD
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-28167000 USD
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-26844000 USD
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-6980000 USD
CY2017Q4 us-gaap Notes Payable
NotesPayable
9922000 USD
CY2018Q4 us-gaap Notes Payable
NotesPayable
10298000 USD
CY2017Q4 us-gaap Notes Payable Current
NotesPayableCurrent
0 USD
CY2018Q4 us-gaap Notes Payable Current
NotesPayableCurrent
2294000 USD
CY2018 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-7312000 USD
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-5834000 USD
CY2017Q4 us-gaap Net Income Loss
NetIncomeLoss
-6386000 USD
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-26512000 USD
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-4661000 USD
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-8714000 USD
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-9011000 USD
CY2018Q4 us-gaap Net Income Loss
NetIncomeLoss
-10317000 USD
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-32703000 USD
CY2017Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6985000 USD
CY2017Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7312000 USD
CY2017Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5834000 USD
CY2017Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6386000 USD
CY2017 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-26517000 USD
CY2018Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4661000 USD
CY2018Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8714000 USD
CY2018Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9011000 USD
CY2018Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10317000 USD
CY2018 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-32703000 USD
CY2017 us-gaap Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1
NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
1076000 USD
CY2018 us-gaap Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1
NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
0 USD
CY2017 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
403000 USD
CY2018 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1254000 USD
CY2017 us-gaap Operating Expenses
OperatingExpenses
30535000 USD
CY2018 us-gaap Operating Expenses
OperatingExpenses
41470000 USD
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-26532000 USD
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-33084000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
681000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
404000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
277000 USD
CY2018Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
97900000 USD
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
102000 USD
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
174000 USD
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
50000 USD
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
50000 USD
CY2017 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
0 USD
CY2018 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-3000 USD
CY2017Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
152000 USD
CY2018Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
66000 USD
CY2017Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-41000 USD
CY2017Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
38000 USD
CY2017Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
55000 USD
CY2017Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-32000 USD
CY2018Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-42000 USD
CY2018Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
147000 USD
CY2018Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
140000 USD
CY2018Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
136000 USD
CY2017Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1500000 USD
CY2017 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
0 USD
CY2018 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
62462000 USD
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
246000 USD
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
445000 USD
CY2017 us-gaap Preferred Stock Accretion Of Redemption Discount
PreferredStockAccretionOfRedemptionDiscount
5000 USD
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2971000 USD
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2865000 USD
CY2017 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
10000000 USD
CY2018 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0 USD
CY2017 us-gaap Proceeds From Repayment Of Loans By Employee Stock Ownership Plans
ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans
110000 USD
CY2018 us-gaap Proceeds From Repayment Of Loans By Employee Stock Ownership Plans
ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans
242000 USD
CY2017 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
0 USD
CY2018 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
33000000 USD
CY2017 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 USD
CY2018 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 USD
CY2017 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
307000 USD
CY2017 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
300000 USD
CY2018 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
182000 USD
CY2018 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
200000 USD
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3398000 USD
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3817000 USD
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
563000 USD
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
727000 USD
CY2017 us-gaap Reclassifications Of Temporary To Permanent Equity
ReclassificationsOfTemporaryToPermanentEquity
76981000 USD
CY2018 us-gaap Reclassifications Of Temporary To Permanent Equity
ReclassificationsOfTemporaryToPermanentEquity
0 USD
CY2017 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
4667000 USD
CY2018 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0 USD
CY2017Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4120000 USD
CY2017Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5487000 USD
CY2017Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5018000 USD
CY2017Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4998000 USD
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19623000 USD
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6413000 USD
CY2018Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8375000 USD
CY2018Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7399000 USD
CY2018Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8234000 USD
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
30421000 USD
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-93593000 USD
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-126296000 USD
CY2017Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
462000 USD
CY2017Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
718000 USD
CY2017Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1631000 USD
CY2017Q4 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1192000 USD
CY2017 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
4003000 USD
CY2018Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
4784000 USD
CY2018Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
2182000 USD
CY2018Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
944000 USD
CY2018Q4 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
476000 USD
CY2018 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
8386000 USD
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
2409000 USD
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
3679000 USD
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
902720 shares
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
4182404 shares
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
3800000 USD
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1600000 USD
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
2698000 USD
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
2421000 USD
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
1979000 shares
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
4.20
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
2698000 USD
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
3527000 shares
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
5.76
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y11M12D
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P5Y7M10D
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y11M12D
CY2017Q4 us-gaap Short Term Investments
ShortTermInvestments
0 USD
CY2018Q4 us-gaap Short Term Investments
ShortTermInvestments
29875000 USD
CY2017 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
204000 USD
CY2017 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
110000 USD
CY2018 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
242000 USD
CY2017 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
307000 USD
CY2018 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
182000 USD
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
-61921000 USD
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
38510000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
51344000 USD
CY2017 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
5000 USD
CY2018 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
0 USD
CY2017 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-3800000 USD
CY2018 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
10600000 USD
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
19244605 shares
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
29600332 shares
CY2018 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of Credit Risk</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, which include short-term investments that have maturities of less than three months. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts. The Company invests its excess cash primarily in deposits and money market funds held with one financial institution.</font></div></div>
CY2018 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s consolidated financial statements are prepared in accordance with U.S.&#160;GAAP, which requires it to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Although these estimates are based on the Company&#8217;s knowledge of current events and actions it may take in the future, actual results may ultimately differ from these estimates and assumptions.</font></div></div>

Files In Submission

Name View Source Status
0001590750-19-000013-index-headers.html Edgar Link pending
0001590750-19-000013-index.html Edgar Link pending
0001590750-19-000013.txt Edgar Link pending
0001590750-19-000013-xbrl.zip Edgar Link pending
advancedprograms.jpg Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
mgen-12312018x10k.htm Edgar Link pending
mgen-12312018xex10178.htm Edgar Link pending
mgen-12312018xex211.htm Edgar Link pending
mgen-12312018xex231.htm Edgar Link pending
mgen-12312018xex311.htm Edgar Link pending
mgen-12312018xex312.htm Edgar Link pending
mgen-12312018xex321.htm Edgar Link pending
mgen-20181231.xml Edgar Link completed
mgen-20181231.xsd Edgar Link pending
mgen-20181231_cal.xml Edgar Link unprocessable
mgen-20181231_def.xml Edgar Link unprocessable
mgen-20181231_lab.xml Edgar Link unprocessable
mgen-20181231_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending